Why the study?
Duchenne muscular dystrophy patients develop myocardial fibrosis before functional impairment, suggesting earlier antifibrotic treatment may be beneficial.
Does early treatment with lisinopril and spironolactone improve cardiac and skeletal muscle function in a mouse model of Duchenne muscular dystrophy?
Comparison
Spironolactone and lisinopril starting at 4 weeks or 8 weeks versus untreated
Design
Preclinical study with three groups of 10 mice
Follow-up
Until 20 weeks of age
Authors
Loading...
May support earlier lisinopril-spironolactone in DMD mouse models; leaves open human translation and optimal timing.
Does early treatment with lisinopril and spironolactone improve cardiac and skeletal muscle function in a mouse model of Duchenne muscular dystrophy?
Early initiation of lisinopril and spironolactone significantly attenuates myocardial disease and improves skeletal myopathy in a mouse model of Duchenne muscular dystrophy.
Rafael‐Fortney et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: